Two-month landmark analysis for OS
| Immune variable* . | n . | HR (95% CI) . | P . |
|---|---|---|---|
| ALC | 90 | 0.67 (0.34-1.31) | .246 |
| CD3+ T cells | 90 | 0.73 (0.45-1.18) | .219 |
| CD4+ T cells | 90 | 0.69 (0.43-1.12) | .150 |
| CD4+CD45RA+ T cells | 90 | 1.11 (0.75-1.64) | .587 |
| CD8+ T cells | 90 | 1.00 (0.66-1.49) | .984 |
| NK cells | 78 | 1.34 (0.63-2.84) | .439 |
| B cells | 90 | 0.85 (0.68-1.07) | .163 |
| PHA | 88 | 0.56 (0.40-0.78)† | .009 |
| Immune variable* . | n . | HR (95% CI) . | P . |
|---|---|---|---|
| ALC | 90 | 0.67 (0.34-1.31) | .246 |
| CD3+ T cells | 90 | 0.73 (0.45-1.18) | .219 |
| CD4+ T cells | 90 | 0.69 (0.43-1.12) | .150 |
| CD4+CD45RA+ T cells | 90 | 1.11 (0.75-1.64) | .587 |
| CD8+ T cells | 90 | 1.00 (0.66-1.49) | .984 |
| NK cells | 78 | 1.34 (0.63-2.84) | .439 |
| B cells | 90 | 0.85 (0.68-1.07) | .163 |
| PHA | 88 | 0.56 (0.40-0.78)† | .009 |
P values significant at the .01 level are indicated in bold.
In univariable analysis of patient and graft variables, only recipient age was significantly associated with OS (hazard ratio [HR], 2.11 [95% CI, 1.30-3.43] per decade, P = .001). Patient sex, diagnosis, CMV seropositivity, engrafting CB unit–recipient HLA-match, engrafting CB unit infused viable CD34+ and CD3+ cell doses, addition of haploidentical CD34+ cells were not significant.
HR adjusted for age.